Celgene and bluebird Announce Results from Ongoing Study of bb2121 antiBCMA CAR T Cell Therapy in Patients with Multiple Myeloma Published in NEJM

Celgene and bluebird Announce Results from Ongoing Study of bb2121 anti-BCMA CAR T Cell Therapy in Patients with Multiple Myeloma Published in NEJM

14:35 EDT 2 May 2019 | Speciality Pharma Journal

SUMMIT, N.J. & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Celgene Corporation (Nasdaq: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that the New England Journal of Medicine (NEJM) has published interim results from CRB-401, the ongoing phase 1 study of bb2121, the companies’ lead investigational BCMA-targeted chimeric antigen receptor (CAR) T-cell therapy candidate for patients with relapsed and refractory multiple …

More From BioPortfolio on "Celgene and bluebird Announce Results from Ongoing Study of bb2121 anti-BCMA CAR T Cell Therapy in Patients with Multiple Myeloma Published in NEJM"